×

Big pharma tax attack

8:04 AM ET Tue, 29 July 2014

Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.